Name: UMIN ID:
Unique ID issued by UMIN | UMIN000022254 |
---|---|
Receipt number | R000025612 |
Scientific Title | Phase II Clinical Trial of Dasatinib Therapy Aiming for Treatment-Free Remission in Patients with Chronic Phase Chronic Myeloid Leukemia |
Date of disclosure of the study information | 2016/05/21 |
Last modified on | 2023/11/26 14:21:51 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2016/05/09 21:48:31 | ||
2 | Update | 2016/05/23 18:48:37 | Acronym Acronym |
|
3 | Update | 2016/06/20 11:33:46 | Recruitment status |
|
4 | Update | 2018/05/15 18:28:39 | Recruitment status |
|
5 | Update | 2018/11/15 18:28:08 | Email Email1 |
|
6 | Update | 2019/05/16 18:41:27 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Address TEL Last name of contact person Last name of contact person Zip code Address TEL Organization Organization Address Address Tel Secondary IDs Study ID_1 Org. issuing International ID_1 Org. issuing International ID_1 |
|
7 | Update | 2019/05/16 18:43:38 | Address |
|
8 | Update | 2019/05/16 18:50:53 | Date of IRB Last follow-up date |
|
9 | Update | 2019/05/20 12:45:17 | Address Address |
|
10 | Update | 2019/11/14 17:14:28 | Recruitment status |
|
11 | Update | 2019/11/14 17:15:10 | Number of participants that the trial has enrolled |
|
12 | Update | 2020/05/22 10:24:11 | Last follow-up date Date analysis concluded |
|
13 | Update | 2023/11/26 14:19:07 | Recruitment status |
|
14 | Update | 2023/11/26 14:21:51 | URL releasing protocol Publication of results URL related to results and publications Results Results Results date posted Baseline Characteristics Baseline Characteristics Participant flow Participant flow Adverse events Adverse events Outcome measures Outcome measures |